Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Diseases | 4 | 2020 | 136 | 1.790 |
Why?
|
| Back | 2 | 2022 | 11 | 0.940 |
Why?
|
| Erythema | 2 | 2022 | 29 | 0.920 |
Why?
|
| Skin Neoplasms | 5 | 2022 | 897 | 0.920 |
Why?
|
| Alopecia Areata | 1 | 2024 | 11 | 0.890 |
Why?
|
| Osteoarthritis, Hip | 1 | 2024 | 62 | 0.830 |
Why?
|
| Chondrosarcoma | 1 | 2022 | 13 | 0.740 |
Why?
|
| Hyperkeratosis, Epidermolytic | 2 | 2023 | 4 | 0.710 |
Why?
|
| Osteoarthritis, Knee | 1 | 2024 | 273 | 0.690 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2020 | 31 | 0.660 |
Why?
|
| Insect Bites and Stings | 1 | 2020 | 39 | 0.650 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2020 | 100 | 0.620 |
Why?
|
| Antigens, CD1 | 1 | 2019 | 23 | 0.620 |
Why?
|
| Histiocytosis | 1 | 2019 | 19 | 0.620 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 122 | 0.590 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 333 | 0.560 |
Why?
|
| Imipramine | 1 | 2017 | 18 | 0.550 |
Why?
|
| Hyperpigmentation | 1 | 2017 | 13 | 0.550 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 25 | 0.550 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 445 | 0.530 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 293 | 0.530 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2020 | 156 | 0.530 |
Why?
|
| Ear Diseases | 1 | 2016 | 22 | 0.510 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 17 | 0.510 |
Why?
|
| Keratin-1 | 1 | 2016 | 1 | 0.500 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2016 | 6 | 0.500 |
Why?
|
| Purpura Fulminans | 1 | 2015 | 6 | 0.490 |
Why?
|
| Angiokeratoma | 1 | 2015 | 1 | 0.480 |
Why?
|
| Pseudolymphoma | 1 | 2015 | 4 | 0.480 |
Why?
|
| Nail Diseases | 1 | 2015 | 15 | 0.470 |
Why?
|
| Diagnosis, Differential | 5 | 2022 | 1966 | 0.460 |
Why?
|
| Pemphigus | 1 | 2014 | 5 | 0.460 |
Why?
|
| Photosensitivity Disorders | 1 | 2014 | 11 | 0.440 |
Why?
|
| West Nile virus | 1 | 2015 | 117 | 0.430 |
Why?
|
| Drug Eruptions | 1 | 2014 | 34 | 0.430 |
Why?
|
| Fluorouracil | 1 | 2014 | 138 | 0.430 |
Why?
|
| Deoxycytidine | 1 | 2014 | 83 | 0.430 |
Why?
|
| Immunoglobulin A | 1 | 2014 | 218 | 0.420 |
Why?
|
| West Nile Fever | 1 | 2015 | 139 | 0.420 |
Why?
|
| Depressive Disorder | 1 | 2017 | 481 | 0.420 |
Why?
|
| Gout | 1 | 2016 | 167 | 0.410 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 194 | 0.390 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 348 | 0.380 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2020 | 69 | 0.360 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1541 | 0.360 |
Why?
|
| Sporotrichosis | 1 | 2011 | 1 | 0.360 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 803 | 0.360 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2020 | 15 | 0.340 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 103 | 0.320 |
Why?
|
| Rituximab | 2 | 2020 | 167 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 1348 | 0.310 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 127 | 0.300 |
Why?
|
| Bone Marrow | 2 | 2020 | 327 | 0.290 |
Why?
|
| Humans | 22 | 2024 | 132256 | 0.280 |
Why?
|
| Aged | 9 | 2024 | 21483 | 0.270 |
Why?
|
| Mutation | 3 | 2023 | 6250 | 0.270 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 1718 | 0.250 |
Why?
|
| Face | 3 | 2019 | 189 | 0.230 |
Why?
|
| Dermatology | 1 | 2024 | 30 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2024 | 240 | 0.200 |
Why?
|
| Female | 11 | 2024 | 70791 | 0.190 |
Why?
|
| Necrosis | 1 | 2022 | 210 | 0.180 |
Why?
|
| Consensus | 1 | 2024 | 658 | 0.170 |
Why?
|
| Skin | 2 | 2023 | 527 | 0.170 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2020 | 29 | 0.170 |
Why?
|
| Cyclin D1 | 1 | 2020 | 113 | 0.160 |
Why?
|
| Awareness | 1 | 2020 | 80 | 0.160 |
Why?
|
| Plasma Cells | 1 | 2020 | 56 | 0.160 |
Why?
|
| Male | 9 | 2024 | 65018 | 0.160 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2020 | 16 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 222 | 0.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2020 | 64 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 40 | 0.160 |
Why?
|
| Eyelid Neoplasms | 1 | 2020 | 28 | 0.160 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 216 | 0.160 |
Why?
|
| Immunophenotyping | 1 | 2020 | 343 | 0.160 |
Why?
|
| Histiocytes | 1 | 2019 | 24 | 0.160 |
Why?
|
| Curriculum | 1 | 2024 | 765 | 0.150 |
Why?
|
| Biopsy, Needle | 2 | 2020 | 234 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2020 | 364 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 305 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 358 | 0.140 |
Why?
|
| Cataract | 1 | 2020 | 168 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 768 | 0.140 |
Why?
|
| Rare Diseases | 2 | 2020 | 208 | 0.130 |
Why?
|
| Ear Neoplasms | 1 | 2016 | 14 | 0.130 |
Why?
|
| Biopsy | 1 | 2020 | 1288 | 0.130 |
Why?
|
| Neck | 1 | 2017 | 142 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2020 | 13030 | 0.120 |
Why?
|
| Gangrene | 1 | 2015 | 27 | 0.120 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2015 | 66 | 0.120 |
Why?
|
| Fingers | 1 | 2015 | 67 | 0.110 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2014 | 12 | 0.110 |
Why?
|
| Capecitabine | 1 | 2014 | 18 | 0.110 |
Why?
|
| Adult | 3 | 2024 | 31620 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2024 | 1258 | 0.110 |
Why?
|
| Middle Aged | 4 | 2024 | 29026 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1965 | 0.100 |
Why?
|
| Nose Neoplasms | 2 | 2011 | 32 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 7140 | 0.090 |
Why?
|
| Sporothrix | 1 | 2011 | 1 | 0.090 |
Why?
|
| Itraconazole | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cats | 1 | 2011 | 118 | 0.090 |
Why?
|
| Risk Factors | 1 | 2024 | 10946 | 0.080 |
Why?
|
| Aminoquinolines | 1 | 2008 | 34 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2011 | 314 | 0.070 |
Why?
|
| Mohs Surgery | 1 | 2008 | 38 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2023 | 8548 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17396 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 623 | 0.060 |
Why?
|
| Prognosis | 1 | 2015 | 5016 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1829 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2024 | 71 | 0.050 |
Why?
|
| Melanoma | 1 | 2011 | 954 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2019 | 14736 | 0.050 |
Why?
|
| Child | 2 | 2015 | 25784 | 0.050 |
Why?
|
| Cataract Extraction | 1 | 2020 | 152 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 665 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3995 | 0.030 |
Why?
|
| Keratins | 1 | 2011 | 52 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2011 | 47 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5412 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 34850 | 0.020 |
Why?
|
| Ointments | 1 | 2008 | 13 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2008 | 140 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1295 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1653 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2511 | 0.010 |
Why?
|